About

John C. Fang, MD, is the Division Chief and Professor of Medicine at the University of Utah Hospital and Huntsman Cancer Institute, specializing in Gastroenterology, Hepatology, and Nutrition. His clinical and research interests include Barrett's Esophagus, Enteral Nutrition, Esophageal Diseases, Gastroesophageal Reflux Disease (GERD), and Therapeutic Endoscopy. He has authored and co-authored over 75 peer-reviewed research publications in these areas. Dr. Fang received his Medical Degree from Washington University School of Medicine in 1989 and trained in Internal Medicine at Temple University Hospital and Gastroenterology at the University of Virginia Health Sciences Center. He is board certified by the American Board of Internal Medicine and Gastroenterology. Additionally, he serves as Medical Director of Endoscopy at the University of Utah Hospital and holds leadership roles such as vice-chair of the Ambulatory Endoscopy Centers Special interest group for the American Society for Gastrointestinal Endoscopy, with service on numerous committees for the American Gastroenterological Association and American College of Gastroenterology.

Research topics

• Medicine
• Internal medicine
• Surgery
• Pathology
• Anesthesia
• Gastroenterology
• Radiology

Selected publications

• Tul769 FOOD FOR ARTIFICIAL INTELLIGENCE’S THOUGHTS? ASSESSING DIFFERENCES IN LARGE LANGUAGE MODEL GENERATED DIETARY RECOMMENDATIONS

  Gastroenterology · 2026-05-01

  article
  PublisherDOI

• Interventions for Increasing Colorectal Cancer Screening Uptake: A Systematic Review and Network Meta-Analysis

  Gastroenterology · 2026-04-01

  article
  PublisherDOI

• Phase II trial of encapsulated rapamycin to reduce polyp burden associated with familial adenomatous polyposis

  Clinical Cancer Research · 2026-04-28

  article

  PURPOSE: Familial adenomatous polyposis (FAP) confers a significant risk of colorectal/duodenal cancer. Encapsulated rapamycin (eRapa) has demonstrated promise as FAP chemoprevention in early clinical studies. METHODS: 30 FAP patients enrolled to three dosing regimens of eRapa (0.5 mg): cohort 1 - every other day, cohort 2 - daily every other week, or cohort 3 - daily. The primary endpoints were safety/tolerability, pharmacokinetics, and percentage change from baseline (PCFB) in colorectal polyp burden (CPB) at 6 mos. Secondary endpoints included PCFB total (TPB) and duodenal (DPB) polyp burden, and change in InSiGHT stage and Spigelman score at 6 and 12 mos. RESULTS: 29/ 30 patients (97%) completed the 12-mos study with predictable bioavailability. Low grade adverse events were frequent, but most pronounced in daily dosing. Two patients discontinued treatment related to toxicity. Cohort 1 had the largest decrease median PCFB CPB, DPB, and TPB at 6 mos: -39.4 % (IQR, 108.9; p = 0.28), -33.33 % (IQR, 90.0; p = 0.04), and -38.6 % (IQR, 88.5; p = 0.26), respectively. At 12 mos, Cohort 2 had the largest decrease median PCFB CPB and TPB: -29.3 % (IQR, 67.6; p = 0.37) and -26.3 % (IQR, 49.5; p = 0.29), respectively. Intermittent dosing cohorts (1 & 2) reduced DPB at 6 mos (p = 0.04), and improved TPB at 12 mos (p = 0.05) compared to daily dosing. CONCLUSION: eRapa was safe, tolerable and showed preliminary efficacy for FAP chemoprevention. The 0.5 mg daily every-other-week schedule will be evaluated in an upcoming phase III trial.

  PublisherDOI

• Mo1716 BLOWN OUT MYOTOMY (BOM): AN UNDERRECOGNIZED FINDING AFTER TREATMENT FOR ACHALASIA? A SYSTEMATIC REVIEW & META-ANALYSIS OF INCIDENCE AND CLINICAL DETERMINANTS

  Gastrointestinal Endoscopy · 2026-05-01

  article
  PublisherDOI

• Sa1002 LARGE LANGUAGE MODEL GENERATED PATHOLOGY LETTERS SHARE SIMILAR CHARACTERISTICS

  Gastroenterology · 2026-05-01

  article
  PublisherDOI

• Mo1716 BLOWN OUT MYOTOMY (BOM): AN UNDERRECOGNIZED FINDING AFTER TREATMENT FOR ACHALASIA? A SYSTEMATIC REVIEW & META-ANALYSIS OF INCIDENCE AND CLINICAL DETERMINANTS

  Gastroenterology · 2026-05-01

  article
  PublisherDOI

• 168 DECREASE RECURRENCE OF COLON POLYPS IN ENDOSCOPIC MUCOSAL RESECTION USING MARKED WIDE MARGINS: A RETROSPECTIVE ANALYSIS OF DIFFERENT ENDOSCOPIC MUCOSAL RESECTION TECHNIQUES AND RECURRENCE RATES

  Gastrointestinal Endoscopy · 2026-05-01

  article
  PublisherDOI

• 168 DECREASE RECURRENCE OF COLON POLYPS IN ENDOSCOPIC MUCOSAL RESECTION USING MARKED WIDE MARGINS: A RETROSPECTIVE ANALYSIS OF DIFFERENT ENDOSCOPIC MUCOSAL RESECTION TECHNIQUES AND RECURRENCE RATES

  Gastroenterology · 2026-05-01

  article
  PublisherDOI

• Sa1002 LARGE LANGUAGE MODEL GENERATED PATHOLOGY LETTERS SHARE SIMILAR CHARACTERISTICS

  Gastrointestinal Endoscopy · 2026-05-01

  article
  PublisherDOI

• Tul769 FOOD FOR ARTIFICIAL INTELLIGENCE’S THOUGHTS? ASSESSING DIFFERENCES IN LARGE LANGUAGE MODEL GENERATED DIETARY RECOMMENDATIONS

  Gastrointestinal Endoscopy · 2026-05-01

  article
  PublisherDOI

Recent grants

• NIH Grant M01RR000064

  NIH · $852k · 2008

Frequent coauthors

• Kristen Hilden

  University of Utah

  69 shared

• Kathryn A. Peterson

  University of Utah

  64 shared

• James A. DiSario

  55 shared

• Mark H. DeLegge

  50 shared

• Stephen A. McClave

  University of Louisville

  47 shared

• Douglas G. Adler

  43 shared

• Gregory G. Ginsberg

  40 shared

• William N. Baskin

  University of Illinois Chicago, Rockford campus

  38 shared

Education

• M.D.

  Washington University School of Medicine

  1989

• Other, Internal Medicine

  Temple University Hospital

• Other, Gastroenterology

  University of Virginia Health Sciences Center